Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Friday.

Several other equities research analysts have also commented on the stock. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a report on Friday, August 1st. UBS Group boosted their price objective on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a “buy” rating in a research note on Friday, July 11th. Raymond James Financial initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price objective for the company. Finally, Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $417.38.

Alnylam Pharmaceuticals Trading Down 0.3%

NASDAQ:ALNY opened at $452.00 on Friday. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $469.81. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market cap of $59.25 billion, a P/E ratio of -183.00 and a beta of 0.32. The firm has a 50-day simple moving average of $387.47 and a 200-day simple moving average of $309.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the business posted ($0.13) EPS. The company’s quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of the company’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total transaction of $666,986.55. Following the transaction, the executive vice president owned 20,221 shares in the company, valued at approximately $9,269,508.61. This represents a 6.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the transaction, the director owned 16,804 shares in the company, valued at $7,561,800. The trade was a 40.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,594 shares of company stock worth $25,551,456 in the last three months. 1.50% of the stock is owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in ALNY. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $243,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $612,000. Captrust Financial Advisors boosted its holdings in shares of Alnylam Pharmaceuticals by 32.7% in the 4th quarter. Captrust Financial Advisors now owns 6,414 shares of the biopharmaceutical company’s stock valued at $1,509,000 after acquiring an additional 1,581 shares during the last quarter. Brevan Howard Capital Management LP boosted its holdings in shares of Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 44 shares during the last quarter. Finally, BOKF NA boosted its holdings in shares of Alnylam Pharmaceuticals by 592.7% in the 4th quarter. BOKF NA now owns 381 shares of the biopharmaceutical company’s stock valued at $91,000 after acquiring an additional 326 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.